参考文献/References:
[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2]Melinda S,Pos O,Eva M,et al.Circulating Cell-Free Nucleic Acids:Main Characteristics and Clinical Application[J].Int J Mol Sci,2020,21(18):6827. [3]Ohlsson L,Hall A,Lindahl H,et al.Increased level of circulating cell-free mitochondrial DNA due to a single bout of strenuous physical exercise[J].Eur J Appl Physiol,2020,120(4):897-905. [4]Celec P,Vlková B,Lauková L,et al.Cell-free DNA:the role in pathophysiology and as a biomarker in kidney diseases[J].Expert Rev Mol Med,2018(20):e1. [5]Cristiano S,Leal A,Phallen J,et al.Genome-wide cell-free DNA fragmentation in patients with cancer[J].Nature,2019,570(7761):385-389. [6]Fiala C,Diamandis EP.Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection[J].BMC Med,2018,16(1):166. [7]Phallen J,Sausen M,Adleff V,et al.Direct detection of early-stage cancers using circulating tumor DNA[J].Sci Transl Med,2017,9(403):eaan2415. [8]Duque-Afonso J,Waterhouse M,Pfeifer D,et al.Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation[J].Clinical Biochemistry,2018(52):137-141. [9]Leng S,Zheng J,Jin Y,et al.Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis[J].Clin Chim Acta,2018(477):160-165. [10]Gielis EM,Ledeganck KJ,Dendooven A,et al.The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation[J].Nephrol Dial Transplant,2020,35(4):714-721. [11]Bianchi DW,Chiu RWK.Sequencing of Circulating Cell-free DNA during Pregnancy[J].N Engl J Med,2018,379(5):464-473. [12]Huang ZB,Zhang HT,Yu B,et al.Cell-free DNA as a liquid biopsy for early detection of gastric cance[J].Oncol Lett,2021,21(1):3. [13]Boonstra PA,Wind TT,van Kruchten M,et al.Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy[J].Cancer Metastasis Rev,2020,39(3):999-1013. [14]Yamamoto Y,Uemura M,Fujita M,et al.Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma[J].Cancer Sci,2019(110):617-628. [15]Mouliere F,Chandrananda D,Piskorz AM,et al.Enhanced detection of circulating tumor DNA by fragment size analysis[J].Sci Transl Med,2018,10(466):eaat4921. [16]To EW,Chan KC,Leung SF,et al.Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma[J].Clin Cancer Res,2003,9(9):3254-3259. [17]Muhanna N,Di Grappa MA,Chan HHL,et al.Cell-Free DNA Kinetics in a Pre-clinical Model of Head and Neck Cancer[J].Sci Rep,2017,7(1):16723. [18]Lee Y,Park S,Kim WS,et al.Correlation between progression-free survival,tumor burden,and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer[J].Thorac Cancer,2018(9):1104-1110. [19]Tellez-Gabriel M,Knutsen E,Perander M,et al.Current Status of Circulating Tumor Cells,Circulating Tumor DNA,and Exosomes in Breast Cancer Liquid Biopsies[J].Int J Mol Sci,2020,21(24):9457. [20]Fiala C,Diamandis EP.Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection[J].BMC Med,2018,16(1):166. [21]Phallen J,Sausen M,Adleff V,et al.Direct detection of early-stage cancers using circulating tumor DNA[J].Sci Transl Med,2017,9(403):eaan2415. [22]Strijker M,Soer EC,de Pastena M,et al.Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma[J].Int J Cancer,2020,146(5):1445-1456. [23]Delfau-Larue MH,van der Gucht A,Dupuis J,et al.Total metabolic tumor volume,circulating tumor cells, cell-free DNA:distinct prognostic value in follicular lymphoma[J].Blood Adv,2018,2(7):807-816. [24]Hufnagl C,Leisch M,Weiss L,et al.Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer[J].Oncol Lett,2020,19(2):1551-1558. [25]Sherwood JL,Corcoran C,Brown H,et al.Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA(ctDNA)from Patients with Non-Small Cell Lung Cancer(NSCLC)[J].PLoS One,2016,11(2):e0150197. [26]Wagner JT,Kim HJ,Johnson-Camacho KC,et al.Diurnal stability of cell-free DNA and cell-free RNA in human plasma samples[J].Sci Rep,2020,10(1):16456. [27]Madsen AT,Hojbjerg JA,Sorensen BS,et al.Day-to-day and within-day biological variation of cell-free DNA[J].EBioMedicine,2019(49):284-290. [28]Van Dessel LF,Beije N,Helmijr JC,et al.Application of circulating tumor DNA in prospective clinical oncology trials-standardization of preanalytical conditions[J].Mol Oncol,2017,11(3):295-304. [29]Raymond CK,Hernandez J,Karr R,et al.Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting[J].PLoS One,2017,12(4):e0176241. [30]Leest PV,Boonstra PA,Elst AT,et al.Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients[J].Cancers(Basel),2020,12(5):1222. [31]Mauger F,Dulary C,Daviaud C,et al.Comprehensive evaluation of methods to isolate,quantify,and characterize circulating cell-free DNA from small volumes of plasma[J].Anal Bioanal Chem,2015,407(22):6873-6878. [32]Markus H,Contente-Cuomo T,Farooq M,et al.Evaluation of pre-analytical factors affecting plasma DNA analysis[J].Sci Rep,2018,8(1):7375. [33]Li C,He Q,Liang H,et al.Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer:A Meta-Analysis[J].Front Oncol,2020(10):290. [34]Wehrle J,Philipp U,Jolic M,et al.Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management[J].Diagnostics(Basel),2020,10(8):550. [35]Postel M,Roosen A,Laurent-Puig P,et al.Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA:a cancer diagnostic perspective[J].Expert Rev Mol Diagn,2018,18(1):7-17. [36]Guerrero-Preston R,Báez A,Blanco A,et al.Global DNA methylation:a common early event in oral cancer cases with exposure to environmental carcinogens or viral agents[J].P R Health Sci J,2009,28(1):24-29. [37]Turcas C,Moisoiu V,Stefancu A,et al.SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia[J].Front Oncol,2020(10):1024. [38]Jeltsch A,Jurkowska RZ.New concepts in DNA methylation[J].Trends Biochem Sci,2014,39(7):310-318. [39]Vu TL,Nguyen TT,Doan VTH,et al.Methylation Profiles of BRCA1,RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer[J].Asian Pac J Cancer Prev,2018,19(7):1887-1893. [40]Guan Z,Raut JR,Weigl K,et al.Individual and joint performance of DNA methylation profiles,genetic risk score and environmental risk scores for predicting breast cancer risk[J].Mol Oncol,2020,14(1):42-53. [41]Wilkins OM,Johnson KC,Houseman EA,et al.Genome-wide characterization of cytosine-specific 5-hydroxymethylation in normal breast tissue[J].Epigenetics,2020,15(4):398-418. [42]Qi M,Xiong X.Promoter hypermethylation of RARβ2,DAPK,hMLH1,p14,and p15 is associated with progression of breast cancer:A PRISMA-compliant meta-analysis[J].Medicine(Baltimore),2018,97(51):e13666. [43]Widschwendter M,Evans I,Jones A,et al.Methylation patterns in serum DNA for early identification of disseminated breast cancer[J].Genome Med,2017,9(1):115. [44]Frick E,Gudjonsson T,Eyfjord J,et al.CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer[J].Oncotarget,2019,10(45):4664-4678. [45]Delmonico L,Silva Magalh?es Costa MA,Gomes RJ,et al.Methylation profiling in promoter sequences of ATM and CDKN2A(p14ARF/p16INK4a)genes in blood and cfDNA from women with impalpable breast lesions[J].Oncol Lett,2020,19(4):3003-3010. [46]Douvdevani A,Bernstein-Molho R,Asraf K,et al.Circulating cell-free DNA(cfDNA)levels in BRCA1 and BRCA2 mutation carriers:A preliminary study[J].Cancer Biomark,2020,28(3):269-273. [47]Liu L,Sun L,Li C,et al.Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.Biomed Mater Eng[J].Biomed Mater Eng,2015(26 Suppl 1):S2217-S2222. [48]Nunes SP,Moreira-Barbosa C,Salta S,et al.Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women[J].Cancers(Basel),2018,10(10):357. [49]Iqbal S,Vishnubhatla S,Raina V,et al.Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer[J].Springerplus,2015(4):265. [50]Tang Z,Li L,Shen L,et al.Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer:A Comparative Study With CEA and CA15-3[J].Lab Med,2018,49(4):323-328. [51]Ritter M,Paradiso V,Widmer P,et al.Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer:A Feasibility Study[J].Clin Breast Cancer,2020,20(5):413-421. [52]Fernandez-Garcia D,Hills A,Page K,et al.Plasma cell-free DNA(cfDNA)as a predictive and prognostic marker in patients with metastatic breast cancer[J].Breast Cancer Res,2019,21(1):149. [53]Stover DG,Parsons HA,Ha G,et al.Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer[J].Clin Oncol,2018,36(6):543-553. [54]Cheng J,Holland-Letz T,Wallwiener M,et al.Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer[J].Breast Cancer Res Treat,2018,169(1):69-82. [55]Pairawan S,Hess KR,Janku F,et al.Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer[J].Clin Cancer Res,2020,26(8):1924-1931. [56]Kujala J,Hartikainen JM,Tengstrom M,et al.High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival[J].Cancer Med,2020,9(16):5922-5931. [57]Guan G,Wang Y,Sun Q,et al.Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients[J].Cancer Biomark,2020,28(1):111-119.